ADC Therapeutics SA is rated a Strong Buy due to its pivotal ZYNLONTA combination trials for second-line relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The phase 3 LOTIS-5 trial topline data, combining ZYNLONTA with rituximab, is anticipated in Q2 2026 and represents a key milestone. Additionally, the phase 1b LOTIS-7 trial combining ZYNLONTA with glofitamab has shown an 89.8% overall response rate and 77.6% complete response rate, with more data expected by the end of 2026. The company’s $231 million cash runway extends into 2028, reducing near-term dilution risk and supporting ongoing clinical development.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
